These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 38319613)

  • 1. Effects of allisartan-isoproxil-based combination antihypertensive regimen in hypertensive patients with microalbuminuria or hyperuricemia.
    Sun N; Wang H
    J Clin Hypertens (Greenwich); 2024 Mar; 26(3):241-250. PubMed ID: 38319613
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of Allisartan Isoproxil in the Treatment of Mild-to-Moderate Essential Hypertension.
    Wang H; Xi Y; Chen Y; Wang L; Yang F; Lu X; Sun N
    Am J Hypertens; 2023 Sep; 36(10):561-567. PubMed ID: 37343187
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized, double blind, placebo-controlled, multicenter phase II trial of Allisartan Isoproxil in essential hypertensive population at low-medium risk.
    Li Y; Li XH; Huang ZJ; Yang GP; Zhang GG; Zhao SP; Guo Y; Lu SJ; Ma JL; Meng FB; Chen P; Yuan H
    PLoS One; 2015; 10(2):e0117560. PubMed ID: 25693004
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of Hypertensive Patients With Diabetes and Microalbuminuria With Combination Indapamide SR/Amlodipine: Retrospective Analysis of NESTOR.
    Hanon O; Boully C; Caillard L; Labourée F; Cochiello S; Chaussade E
    Am J Hypertens; 2015 Aug; 28(8):1064-71. PubMed ID: 25628416
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination of antihypertensive therapy in the elderly, multicenter investigation (CAMUI) trial: results after 1 year.
    Sato N; Saijo Y; Sasagawa Y; Morimoto H; Takeuchi T; Sano H; Koyama S; Takehara N; Morita K; Sumitomo K; Maruyama J; Kikuchi K; Hasebe N;
    J Hypertens; 2013 Jun; 31(6):1245-55. PubMed ID: 23492647
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prospective direct comparison of antihypertensive effect and safety between high-dose amlodipine or indapamide in hypertensive patients uncontrolled by standard doses of angiotensin receptor blockers and amlodipine.
    Okamura K; Shirai K; Totake N; Okuda T; Urata H
    Clin Exp Hypertens; 2018; 40(2):99-106. PubMed ID: 28692311
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Allisartan Isoproxil Improves Endothelial Function and Vascular Damage in Patients with Essential Hypertension: A Single-Center, Open-Label, Randomized Controlled Trial.
    Zhang G; Fan Y; Qiu Y; Zhou Z; Zhang J; Wang Z; Liu Y; Liu X; Tao J
    Adv Ther; 2020 Aug; 37(8):3551-3561. PubMed ID: 32583313
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of renin-angiotensin system inhibition on microalbuminuria in type 2 diabetes: a post hoc analysis of the Shiga Microalbuminuria Reduction Trial (SMART).
    ; Uzu T; Sawaguchi M; Maegawa H; Kashiwagi A
    Hypertens Res; 2008 Jun; 31(6):1171-6. PubMed ID: 18716365
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of amlodipine, efonidipine, and trichlormethiazide on home blood pressure and upper-normal microalbuminuria assessed by casual spot urine test in essential hypertensive patients.
    Hosaka M; Inoue R; Satoh M; Watabe D; Hanazawa T; Ohkubo T; Asayama K; Obara T; Imai Y;
    Clin Exp Hypertens; 2018; 40(5):468-475. PubMed ID: 29172732
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of combination therapy of angiotensin-converting enzyme inhibitor plus calcium channel blocker on urinary albumin excretion in hypertensive microalbuminuric patients with type II diabetes.
    Shigihara T; Sato A; Hayashi K; Saruta T
    Hypertens Res; 2000 May; 23(3):219-26. PubMed ID: 10821130
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The combination of OLmesartan and a CAlcium channel blocker (azelnidipine) or candesartan and a calcium channel blocker (amlodipine) in type 2 diabetic hypertensive patients: the OLCA study.
    Daikuhara H; Kikuchi F; Ishida T
    Diab Vasc Dis Res; 2012 Oct; 9(4):280-6. PubMed ID: 22718810
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of allisartan isoproxil on blood pressure and target organ injury in patients with mild to moderate essential hypertension.
    Zhang JQ; Yang GH; Zhou X; Liu JX; Shi R; Dong Y; Chen SB; Li YM
    Medicine (Baltimore); 2019 Mar; 98(12):e14907. PubMed ID: 30896643
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.
    Fici F; Ari Bakir E; Ilkay Yüce E; Kanuncu S; Makel W; Tarim BA; Robles NR
    High Blood Press Cardiovasc Prev; 2020 Feb; 27(1):43-49. PubMed ID: 31916208
    [TBL] [Abstract][Full Text] [Related]  

  • 14. S-amlodipine plus chlorthalidone vs. S-amlodipine plus telmisartan in hypertensive patients unresponsive to amlodipine monotherapy: study protocol for a randomized controlled trial.
    Jo SH; Park SJ; Kim EJ; Kim SJ; Cho HJ; Song JM; Shin J; Park JJ; Shin JH; Han KR; Choi DJ
    Trials; 2018 Jun; 19(1):324. PubMed ID: 29925421
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of amlodipine/olmesartan ± hydrochlorothiazide in patients uncontrolled on prior calcium channel blocker or angiotensin II receptor blocker monotherapy.
    Neutel J; Shojaee A; Maa JF
    Adv Ther; 2012 Jun; 29(6):508-23. PubMed ID: 22773358
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The therapeutic advantage of combination antihypertensive drug therapy using amlodipine and irbesartan in hypertensive patients: Analysis of the post-marketing survey data from PARTNER (Practical combination therapy of Amlodin and angiotensin II Receptor blocker; safety and efficacy in patients with hypertension) study.
    Ishimitsu T; Fukuda H; Uchida M; Ishibashi K; Sato F; Nukui K; Nagao M
    Clin Exp Hypertens; 2015; 37(7):542-50. PubMed ID: 25978131
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of up-titration of candesartan versus candesartan plus amlodipine on kidney function in type 2 diabetic patients with albuminuria.
    Okura T; Kojima M; Machida H; Sugiyama M; Kato T; Komada T; Miyazaki T; Ninomiya T; Ichikawa T; Nakatani K; Watanabe Y; Dohi Y; Ito M; Kimura G
    J Hum Hypertens; 2012 Apr; 26(4):214-9. PubMed ID: 21412266
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiproteinuric effects of combined antihypertensive therapies in patients with overt type 2 diabetic nephropathy.
    Kuriyama S; Tomonari H; Tokudome G; Horiguchi M; Hayashi H; Kobayashi H; Ishikawa M; Hosoya T
    Hypertens Res; 2002 Nov; 25(6):849-55. PubMed ID: 12484508
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of olmesartan and amlodipine on blood pressure, endothelial function, and vascular inflammation.
    Honda A; Tahara N; Tahara A; Bekki M; Maeda-Ogata S; Sugiyama Y; Igata S; Nishino Y; Matsui T; Kurata S; Abe T; Yamagishi SI; Fukumoto Y
    J Nucl Cardiol; 2023 Aug; 30(4):1613-1626. PubMed ID: 36737518
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic factors associated with elevation of uric acid after treatment with thiazide-like diuretic in patients with essential hypertension.
    Ohta Y; Kamide K; Hanada H; Morimoto S; Nakahashi T; Takiuchi S; Ishimitsu T; Tsuchihashi T; Soma M; Tomohiro Katsuya T; Sugimoto K; Rakugi H; Oukura T; Higaki J; Matsuura H; Shinagawa T; Miwa Y; Sasaguri T; Igase M; Miki T; Takeda K; Higashiura K; Shimamoto K; Katabuchi R; Ueno M; Hosomi N; Kato J; Komai N; Kojima S; Sase K; Iwashima Y; Yoshihara F; Horio T; Nakamura S; Nakahama H; Miyata T; Kawano Y
    Hypertens Res; 2020 Mar; 43(3):220-226. PubMed ID: 31748705
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.